Excellergy Therapeutics

Excellergy | The First Trifunctional Effector Cell Response Inhibitors (ECRIs)

United States · $70.0M raised

Business Model
B2B
Total Funding
$70.0M
Last Round
$70.0M Series AOct 2025
Rounds
1

About

Excellergy is a biotech company developing Exl-111, the first Trifunctional Effector Cell Response Inhibitor (ECRI), a next-generation anti-IgE therapeutic designed to combine IgE neutralization, receptor-bound IgE removal, and FcεRI downregulation to rapidly desensitize allergic patients. Co-founded by immunologist Dr. Alexander Eggel, the underlying science was validated through Nature-published research and a collaboration with Stanford University.

Summary

Excellergy Therapeutics is a Biotech company based in United States. It has raised $70.0M in total across 1 round, most recently a $70.0M Series A round in Oct 2025. Investors include Samsara BioCapital, Red Tree Venture Capital and Decheng Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AOct 2025
$70.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Excellergy Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/excellergy-therapeutics"><img src="https://indexed.vc/api/badge/company/excellergy-therapeutics" alt="Excellergy Therapeutics on Indexed.vc" width="260" height="76" /></a>